InvestorsObserver
×
News Home

Should You Hold Celldex Therapeutics, Inc. (CLDX) in Biotechnology Industry?

Thursday, April 15, 2021 09:55 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Hold Celldex Therapeutics, Inc. (CLDX) in Biotechnology Industry?

The 63 rating InvestorsObserver gives to Celldex Therapeutics, Inc. (CLDX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 93 percent of stocks in the Biotechnology industry, CLDX’s 63 overall rating means the stock scores better than 63 percent of all stocks.

Overall Score - 63
CLDX has an Overall Score of 63. Find out what this means to you and get the rest of the rankings on CLDX!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Celldex Therapeutics, Inc. Stock Today?

Celldex Therapeutics, Inc. (CLDX) stock is trading at $23.94 as of 9:53 AM on Thursday, Apr 15, a rise of $1.67, or 7.5% from the previous closing price of $22.27. The stock has traded between $22.76 and $24.08 so far today. Volume today is below average. So far 31,967 shares have traded compared to average volume of 819,288 shares.

Click Here to get the full Stock Score Report on Celldex Therapeutics, Inc. (CLDX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App